Dilated cardiomyopathy future or investigational therapies: Difference between revisions
No edit summary |
|||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
{{Dilated cardiomyopathy}} | {{Dilated cardiomyopathy}} | ||
{{CMG}}; {{AE}}{{AIA}} | |||
==Overview== | |||
New promising treatments for [[dilated cardiomyopathy]] include -among others- [[stem cell]]-based treatments, [[cholesterol]]-lowering drugs in combination with [[angiotensin receptor blocker]]<nowiki/>s, and protein A immunoadsorption. | |||
==Future or Investigational Therapies== | |||
There are several new therapies, currently under investigation for [[dilated cardiomyopathy]]. The most promising of these therapies include: | |||
*[[Stem cell]]-based treatments: Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) | |||
*[[Cholesterol]] lowering drugs as [[Simvastatin]] or rosuvaststin, alone or in combination with [[angiotensin receptor blocker]]<nowiki/>s as [[valsartan]] or [[olmesartan]]. | |||
* Protein A Immunoadsorption: an [[extracorporeal]] technique used for the removal of IgG antibodies and molecules. | |||
* Other drugs under investigation include Qiliqiangxin, [[Ranolazine]], and [[Benazepril]].<ref>{{Cite web|url=https://clinicaltrials.gov/ct2/results?cond=dilated+cardiomyopathy&term=&cntry=&state=&city=&dist=|title=Currently ongoing trials on new therapies for dilated cardiomyopathies.|last=Clinicaltrials.gov|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref><br /> | |||
==References== | ==References== | ||
| Line 11: | Line 22: | ||
[[Category:Cardiomyopathy]] | [[Category:Cardiomyopathy]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Up-To-Date cardiology]] | |||
[[Category:Up-To-Date]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 17:55, 30 December 2019
|
Dilated cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dilated cardiomyopathy future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Dilated cardiomyopathy future or investigational therapies |
|
FDA on Dilated cardiomyopathy future or investigational therapies |
|
CDC on Dilated cardiomyopathy future or investigational therapies |
|
Dilated cardiomyopathy future or investigational therapies in the news |
|
Blogs on Dilated cardiomyopathy future or investigational therapies |
|
Risk calculators and risk factors for Dilated cardiomyopathy future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdelrahman Ibrahim Abushouk, MD[2]
Overview
New promising treatments for dilated cardiomyopathy include -among others- stem cell-based treatments, cholesterol-lowering drugs in combination with angiotensin receptor blockers, and protein A immunoadsorption.
Future or Investigational Therapies
There are several new therapies, currently under investigation for dilated cardiomyopathy. The most promising of these therapies include:
- Stem cell-based treatments: Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC])
- Cholesterol lowering drugs as Simvastatin or rosuvaststin, alone or in combination with angiotensin receptor blockers as valsartan or olmesartan.
- Protein A Immunoadsorption: an extracorporeal technique used for the removal of IgG antibodies and molecules.
- Other drugs under investigation include Qiliqiangxin, Ranolazine, and Benazepril.[1]
References
- ↑ Clinicaltrials.gov. "Currently ongoing trials on new therapies for dilated cardiomyopathies".